ABSTRACT-We studied the effects of (•})-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl Keywords:
Y-24180 , Platelet-activating factor (PAF)-receptor antagonist , Eosinophil,
Interleukin-5
Infiltration of inflammatory cells such as eosinophils and lymphocytes into the airway mucosa and lumen is one of the dominant pathological features seen in bron chial asthma (1-3).
Epithelial damage ensues after infiltration of inflammatory cells. Epithelial damage may play an important role in airway hyperresponsiveness in chronic asthma (4). This damage may be induced by major basic protein (MBP), eosinophil cationic protein (ECP) and eosinophil peroxidase (EPO), each derived from eosinophils. Eosinophils migrate into an inflamed region through the activation by various chemoattract ants. Platelet-activating factor (PAF) has been shown to be a potent chemoattractant for eosinophils (5). Recently, interleukin-5 (IL-5) has been shown to play a crucial role in pulmonary eosinophilia (9-12). Anti-IL-S monoclonal antibody (anti-IL-S mAb) suppresses an tigen-induced eosinophilia in mice (9-11) and guinea pigs (12). These interesting findings have stimulator reseachers to investigate the function of antiasthmatic compounds in IL-5 production and its release.
The aim of this paper is to test the effects of Y-24180 on allergic eosinophilia and IL-5 release in the lungs of oval bumin (OA)-sensitized mice and to compare the effects with those of WEB2086, another PAF antagonist, and prednisolone.
MATERIALS AND METHODS

Animals
Six-week-old, male BALB/c mice (Charles River Japan, Kanagawa) were used. The animals were housed at constant temperature (23±21C) and relative humidity (55 ± 5%) and were allowed free access to food and water. ; the drug to be tested was orally given once a day for 10 days before the first OA challenge. A: twice daily treatment; the drug was orally given twice a day at intervals of 12 hr for 10 days before the first OA challenge. On the day of OA challenge, these drugs were given 1 hr prior to the respective challenge. BALF: bronchoalveolar lavage fluid. Sensitization and challenge were carried out according to the method of Nagai et al. (11), with minor modifica tions. Briefly, mice were actively sensitized with intra peritoneal injection of 10 pg of OA and 1 mg of Al(OH)3 gel dissolved in 0.5 ml of saline twice on the first day and days 12 -14. From days 8 -11 after the second sensitization, mice were challenged 3 times every fourth day by intra tracheal injection of 1 pg of OA dissolved in 50 p1 of saline (Fig. 1) .
Evaluation of the effects of drugs Y-24180, WEB2086 and prednisolone were orally ad ministered once a day for 10 days beginning one day be fore the first OA challenge (single daily dose paradigm). Additionally, WEB2086 was orally administered twice a day at intervals of 12 hr for 10 days (twice daily dose paradigm). The paradigm of drug administration was illustrated in relation to OA challenges (Fig. 2) . 
Bronchoalveolar lavage
The animals were sacrificed by an intraperitoneal injec tion of pentobarbital sodium (160 mg/kg) 24 hr after the last OA challenge. The trachea was cannulated, and the closed airway lumen was washed 4 times with 1 ml of sa line containing 0.1 % of bovine serum albumin (Grade V, Sigma Chemical Co.) pre-warmed at 371C. The broncho alveolar lavage fluid (BALF) was centrifuged at 41C for 10 min (150 x g) to separate it into the supernatant and cell pellet. The supernatant was used for the measure ment of IL-5 level. The cell pellet was suspended in 1 ml of saline. The cell suspension was used for eosinophil counts.
Measurement of the number of eosinophils in the BALF
Total cells were calculated by using a Burker-Turk's counting chamber after the Turk's staining. Eosinophils, neutrophils, macrophages and lymphocytes were calcu lated after centrifugation in Cytospin 3TM (Shandon Southern Instruments, Pittsburgh, PA, USA) and stain ing with May-Giemsa stain.
Measurement of IL-5 released in the BALF
The Effects of drugs on the allergic release of IL-5 in the air way
The level of IL-5 in the BALF of the OA control mice were significantly increased after the last OA challenge (Fig. 5) . Single daily treatment with the highest dose of Y-24180 (3 mg/kg) or with prednisolone (10 mg/kg) sig nificantly suppressed the allergic release of IL-5 by 51% and 54%, respectively (Fig. 5) . However, neither single nor twice daily treatment with WEB2086 was effective against the allergic release of IL-S (Figs. 5 and 6 ).
DISCUSSION
In this paper, the effects of Y-24180 on allergic pul monary eosinophilia and IL-5 release were studied by analyzing the BALF obtained from OA-sensitized mice. Eosinophils are the predominant type of leukocytes found at the locus of inflammation in allergic diseases. In addition, they may contribute to airway hyperresponsive ness by releasing cytotoxic proteins such as MBP, ECP and EPO (4) or lipid mediators including leukotriene (LT) C4 (13) and PAF (14). In this study, we found a large number of eosinophils accumulated in the BALF of OA sensitized mice 24 hr after the last OA challenge (Figs. 3  and 4) .
Single daily treatment with Y-24180 (0.3 3 mg/kg) significantly suppressed the allergic infiltration of eosino phils in the airway (Fig. 3) . However, similar treat ment with WEB2086 was ineffective even at the highest dose of 100 mg/kg. In mice, PAF-induced mortality is suppressed by Y-24180 and WEB2086 with ED50 values of 0.022 and 1.42 mg/kg, respectively (7). This indicates that Y-24180 is approximately 60 times more potent than WEB2086. Therefore, the single daily dose of WEB2086 used in the present study would be sufficient for its PAF antagonism. The inhibition of PAF-induced bronchocon striction in guinea pigs by WEB2086 rapidly diminishes at 3 hr after its administration (15). In contrast, the inhibi tion by Y-24180 seems to last more than 12 hr (15). Thus, the short duration of WEB2086 may probably explain the lack of effectiveness in the single daily treatment. In fact, WEB2086 was found to be effective in suppressing the airway infiltration of eosinophils by twice daily treatment at the lowest dose of 15 mg/kg (Fig. 4) . The result sug gests that PAF plays an important role in the allergic pul monary eosinophilia. Single daily treatment with pred nisolone strongly suppressed the eosinophil infiltration (Fig. 3) . Since several studies have shown that steroids suppress allergic eosinophilia (16 18), our results are consistent with these observations. Recently , it has been known that IL-5 plays an im portant role in the development of eosinophilia (9-12). Single daily treatment with the highest dose of Y-24180 (3 mg/kg) significantly suppressed the allergic release of IL 5 in the airway, but single or twice daily treatment of WEB2086 never suppressed it (Figs. 5 and 6). Thus, the suppression of IL-5 release by Y-24180 seems not to be associated with PAF antagonism. In our model, the highest dose of Y-24180 also suppressed the allergic in crease in lymphocytes in the BALF (data not shown). The suppression of IL-5 release thus may be due to a reduced emigration of IL-5 producing cells such as helper T lym phocytes into the airway. Prednisolone significantly sup pressed the allergic release of IL-5. The suppression of eosinophil emigration by prednisolone would be probably due to the suppression of the IL-5 production of helper T lymphocytes (19). Therefore, it may be important to ex amine whether Y-24180 directly suppress the IL-S produc tion by helper T lymphocytes.
Single daily treatment of Y-24180 (3 mg/kg) suppressed the airway infiltration of eosinophils more effectively compared with twice daily treatment of WEB2086 (Figs. 3  and 4) . Thus, the strong suppression of eosinophil emigration by Y-24180 should be due to not only PAF antagonism but also the suppression of IL-5 release.
In conclusion, single daily treatment with Y-24180 (0.3 3 mg/kg) as well as twice daily treatment with WEB2086 (30-200 mg/kg/day) significantly suppressed the eosinophil infiltration in the airway of OA-sensitized mice. These effects seem to be due to long-lasting PAF antagonism. Moreover, the highest dose of Y-24180 more strongly suppressed the eosinophil infiltration than WEB2086. This additional effect may be due to the sup pression of IL-5 release.
